Evidence map›Paper›PMID 33649208›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.

Bharat Madan, Baoshan Zhang, Kai Xu, Cara W Chao, Sijy O'Dell, Jacy R Wolfe, Gwo-Yu Chuang, Ahmed S Fahad, Hui Geng, Rui Kong and 13 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Optimized single-cell gates for yeast display screening.Protein engineering, design & selection : PEDS · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 1 country.

Bharat MadanDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.ORCID 0000-0002-7376-9991
Baoshan ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Kai XuVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.ORCID 0000-0001-5412-6942
Cara W ChaoVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Sijy O'DellVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Jacy R WolfeDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
Gwo-Yu ChuangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Ahmed S FahadDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
Hui GengVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Rui KongVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Mark K LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.ORCID 0000-0001-7540-9263
Thuy Duong NguyenDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.ORCID 0000-0003-4567-6162
Reda RawiVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Arne SchönDepartment of Biology, John Hopkins University, Baltimore, MD 21218.ORCID 0000-0002-2015-2090
Zizhang ShengDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10027.ORCID 0000-0002-3253-3309
Rajani NimraniaDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
Yiran WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Bob C LinVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Lawrence ShapiroVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Brandon J DeKoskyDepartment of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045; dekosky@ku.edu.ORCID 0000-0001-6406-0836
National Institute of Allergy and Infectious Diseases · USUniversity of Kansas · USAaron Diamond AIDS Research Center · USColumbia University · USJohns Hopkins University · US

Funding

Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LUNTE, SUSAN M · 2012 to 2021
$22.1M
Computational Algorithms, Methods, and Tools for Antibody DesignZICAI005140 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2020 to 2025
$3.4M
The influence of evolutionary landscapes on protective antibody developmentR01AI141452 · NIAID · UNIVERSITY OF COLORADO · PI WHITEHEAD, TIMOTHY ANDREW · 2019 to 2023
$2.8M
Comprehensive analysis of human adaptive immune receptors to elucidate correlates of Epstein-Barr virus disease suppressionDP5OD023118 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2016 to 2022
$2.2M
Comprehensive molecular and functional analyses of anti-HIV-1 broadly neutralizing antibody repertoiresR21AI143407 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES, FORREST, MARCUS LAIRD · 2019 to 2020
$435k
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI141452NIAID NIH HHS R21 AI143407NIGMS NIH HHS P20 GM103638NIGMS NIH HHS P20 GM113117NIH HHS DP5 OD023118
6 · The paper itself

Abstract

Vaccine-based elicitation of broadly neutralizing antibodies holds great promise for preventing HIV-1 transmission. However, the key biophysical markers of improved antibody recognition remain uncertain in the diverse landscape of potential antibody mutation pathways, and a more complete understanding of anti-HIV-1 fusion peptide (FP) antibody development will accelerate rational vaccine designs. Here we survey the mutational landscape of the vaccine-elicited anti-FP antibody, vFP16.02, to determine the genetic, structural, and functional features associated with antibody improvement or fitness. Using site-saturation mutagenesis and yeast display functional screening, we found that 1% of possible single mutations improved HIV-1 envelope trimer (Env) affinity, but generally comprised rare somatic hypermutations that may not arise frequently in vivo. We observed that many single mutations in the vFP16.02 Fab could enhance affinity >1,000-fold against soluble FP, although affinity improvements against the HIV-1 trimer were more measured and rare. The most potent variants enhanced affinity to both soluble FP and Env, had mutations concentrated in antibody framework regions, and achieved up to 37% neutralization breadth compared to 28% neutralization of the template antibody. Altered heavy- and light-chain interface angles and conformational dynamics, as well as reduced Fab thermal stability, were associated with improved HIV-1 neutralization breadth and potency. We also observed parallel sets of mutations that enhanced viral neutralization through similar structural mechanisms. These data provide a quantitative understanding of the mutational landscape for vaccine-elicited FP-directed broadly neutralizing antibody and demonstrate that numerous antigen-distal framework mutations can improve antibody function by enhancing affinity simultaneously toward HIV-1 Env and FP.

Indexed as

MutationAIDS VaccinesBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHumansAIDS VaccinesBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV Antibodiesbroadly neutralizing antibodiesfusion peptideHIV-1 vaccinessomatic hypermutationyeast display

Identifiers

PMID33649208
PMCPMC7958426
OpenAlexW3133714594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.